Injecting nivolumab (Opdivo) immediately into precancerous oral lesions led to discount in lesion measurement and allowed some sufferers to keep away from surgical procedure, in keeping with analysis from a section I scientific trial offered on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly 2026, held April 17-22.
Roughly 5% of the overall inhabitants have precancerous lesions of their mouth that may carry a 1% to 36% threat of development to oral most cancers, relying on the extent of dysplasia (i.e., how irregular the cells of the lesion are) and different components, defined presenter Moran Amit, MD, PhD, a surgeon and assistant professor at The College of Texas MD Anderson Most cancers Heart. Since there aren’t any dependable biomarkers to foretell the danger of development, many sufferers sometimes bear surgical resection of their lesions, however this process is related to excessive morbidity, he mentioned.
“The mouth is the primary conduit to so many various capabilities, together with talking, consuming, ingesting, and respiratory. Take into consideration the final time you had a sore spot in your mouth, how debilitating that was. Now think about a affected person who has to bear surgical procedure at many places of their mouth, again and again because the lesions recur,” mentioned Amit, noting that about 60% of sufferers current with a number of lesions and that the danger of recurrence after surgical procedure might be as excessive as 40%.
Every time a affected person has to bear surgical procedure, they’re dropping quantity of their oral cavity, mostly on the tongue. When you lose a specific amount of your tongue, you can’t articulate anymore, you can’t swallow successfully. Due to precancerous lesions, sufferers can lose their capability to talk and eat. The target of our research was to discover a option to spare sufferers from this oftentimes debilitating surgical procedure.”
Moran Amit, MD, PhD, surgeon and assistant professor, The College of Texas MD Anderson Most cancers Heart
Prior analysis has indicated that remedy with the immune checkpoint inhibitor nivolumab may cut back the dimensions and development threat of precancerous oral lesions, however this remedy, which is delivered systemically by means of intravenous infusion, comes with extreme toxicities, mentioned Amit.
“Whereas efficient, systemic nivolumab can result in toxicities that may not be acceptable for sufferers who don’t even have most cancers but,” he famous.
Amit and colleagues reasoned that injecting a decrease dose (2% to 4% of the intravenous dose) of nivolumab immediately into the oral lesion may successfully deal with the lesion with out inducing the systemic toxicities related to intravenous nivolumab.
To check this speculation, they performed a section I scientific trial to judge the security and efficacy of intralesional nivolumab.
The trial enrolled 29 sufferers with at the least one histologically confirmed, untreated premalignant oral lesion that had a excessive threat of development to oral most cancers attributable to its measurement, location, morphology, or extent of dysplasia, or the affected person’s age or medical historical past. Greater than half of the lesions have been situated on the tongue. Fifteen sufferers had lesions with high-grade (average or extreme) dysplasia; the remaining 14 sufferers had low-grade (delicate) dysplasia.
Sufferers obtained both 10 mg or 20 mg of nivolumab injected immediately into certainly one of their oral lesions each three weeks for a complete of 4 cycles. The trial protocol allowed remedy of just one lesion per affected person as a way to assess whether or not intralesional nivolumab’s results can be systemic or restricted to the positioning of injection. In cases the place sufferers had a couple of lesion, the biggest lesion was chosen for remedy.
After a median follow-up of 14.5 months after the primary injection, 25 of 29 sufferers (85%) had skilled a scientific response, outlined as a lower in lesion measurement. Lesion space decreased by a median of 60%, and 19 sufferers skilled reductions higher than 50%. Scientific responses have been noticed for lesions that have been high-grade and people who have been low-grade at baseline. Twelve sufferers (41%) skilled histologic downgrading of their handled lesion, and 6 sufferers had full pathologic response, that means their handled lesion had no indicators of dysplasia on the time of follow-up. Of the six sufferers with full pathologic response, 4 had average dysplasia earlier than remedy, and two had delicate dysplasia.
Twelve months after remedy, 82.13% of handled lesions continued to be most cancers free. For the six sufferers whose handled lesions progressed to most cancers, the progressions have been detected early, and the lesions have been surgically eliminated. Not one of the sufferers whose lesions did not progress required or opted for surgical resection of their handled lesions through the follow-up time.
Serum ranges of nivolumab have been constantly 10-fold decrease than sometimes noticed with systemic administration. No dose-limiting toxicities occurred with intralesional remedy. The most typical adversarial occasions have been fatigue, diarrhea, and rash. Gentle injection-site reactions occurred in 40% of injections however resolved inside 48 hours with out intervention. Most adversarial occasions have been grade 1 or 2, however there was one case every of grade 3 diarrhea, grade 3 hyperglycemia, and grade 4 acidosis.
All however 4 enrolled sufferers accomplished all remedy cycles and monitoring. Sufferers’ signs, resembling these associated to swallowing, mouth and throat soreness, voice, communication, style, and vitamin, both improved or remained steady throughout remedy and follow-up, in keeping with patient-reported outcomes. Sufferers reported higher enjoyment of life and elevated bodily exercise after remedy as in contrast with baseline.
The researchers additionally examined tissue samples from 23 sufferers to find out how intralesional nivolumab impacted the immune microenvironment of handled and untreated lesions. They noticed immune activation completely within the handled lesions, as indicated by higher infiltration of CD4+ T cells, CD8+ T cells, and activated dendritic cells, in addition to immune-cell interactions indicative of adaptive immune responses. Untreated lesions from the identical sufferers didn’t exhibit immune adjustments, which, in keeping with Amit, means that intralesional supply successfully restricted nivolumab’s operate to focus on websites.
“Our findings show that intralesional supply of nivolumab is secure, properly tolerated, and leads to efficacy charges unparalleled by different nonsurgical strategies, which allowed us to spare surgical procedure for almost all of patients-spare removing of items of their mouth, whether or not it is the tongue, the cheek, the ground of their mouth, or their palate,” mentioned Amit. “Even when a affected person finally ends up present process surgical procedure later, the common 60% discount in lesion measurement from intralesional nivolumab means we will considerably decrease the quantity of surgical procedure they’re going to want down the highway, which might hopefully translate to a a lot decrease influence on their high quality of life.”
Amit famous that the findings could have implications past oral lesions. “Many most cancers sorts are preceded by precursor lesions, resembling these arising on the pores and skin, cervix, or colon. Our outcomes increase the chance that native immunotherapy administration could possibly be an efficient interception technique for these precancerous lesions as properly.”
Limitations of the research embody the single-arm design, quick follow-up time, and the truth that the research was not statistically powered to evaluate efficacy.
The research was supported by the Most cancers Prevention and Analysis Institute of Texas.
Supply:
American Affiliation for Most cancers Analysis
